Landmark trial
Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial
Brown PD, Ballman KV, Cerhan JH, et al. · Alliance / CCTG
DoseLab summary
Phase 3 trial (NCCTG N107C/CEC.3) after resection of a brain metastasis: cavity SRS preserved cognition better than whole-brain radiotherapy, with no difference in survival. Citation checked against Crossref.
Why this is useful
The trial behind post-operative cavity SRS instead of whole-brain treatment.
Reference details
- Title
- Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial
- Authors / organization
- Brown PD, Ballman KV, Cerhan JH, et al. · Alliance / CCTG
- Publication / protocol
- Lancet Oncol. 2017;18(8):1049–1060
- Version
- Pending verification
- Year
- 2017
- DOI
- 10.1016/S1470-2045(17)30441-2
- Disease sites
- CNS / Brain
- Topics
- SRS, Post-operative, Brain metastases, Landmark trial
- Fractionation context
- Pending verification
- Last reviewed by DoseLab
- Pending verification